Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Eichenbaum

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Ophthalmology. Retina|August 29, 2024
Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular DegenerationPeter A Campochiaro, David Eichenbaum, Margaret A Chang, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 17, 2023
Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study ResultsDavid Callanan, Rahul N Khurana, Raj K Maturi, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|November 8, 2025
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre studyNasiq Hasan, Elham Sadeghi, Luiz H Lima, et al.
Journal of Vitreoretinal Diseases|October 20, 2025
Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic AtrophyPaul Hahn, David Eichenbaum, Dilsher S Dhoot, et al.
Journal of Vitreoretinal Diseases|March 3, 2025
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER StudyAshish Sharma, Frank G Holz, Nilesh Kumar, et al.
Therapeutic Advances in Ophthalmology|August 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degenerationPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
JAMA Ophthalmology|June 27, 2024
Anti-VEGF Pharmaceutical Prior Authorization in Retina PracticesSabin Dang, D Wilkin Parke, Guneet S Sodhi, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Ophthalmology|August 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR TrialJean-François Korobelnik, Paolo Lanzetta, Sergio Leal, et al.
Expert Opinion on Biological Therapy|February 2, 2023
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey)Ashish Sharma, Frank G Holz, Carl D Regillo, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Ophthalmology. Retina|August 29, 2024
Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular DegenerationPeter A Campochiaro, David Eichenbaum, Margaret A Chang, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 17, 2023
Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study ResultsDavid Callanan, Rahul N Khurana, Raj K Maturi, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|November 8, 2025
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre studyNasiq Hasan, Elham Sadeghi, Luiz H Lima, et al.
Journal of Vitreoretinal Diseases|October 20, 2025
Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic AtrophyPaul Hahn, David Eichenbaum, Dilsher S Dhoot, et al.
Journal of Vitreoretinal Diseases|March 3, 2025
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER StudyAshish Sharma, Frank G Holz, Nilesh Kumar, et al.
Therapeutic Advances in Ophthalmology|August 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degenerationPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
JAMA Ophthalmology|June 27, 2024
Anti-VEGF Pharmaceutical Prior Authorization in Retina PracticesSabin Dang, D Wilkin Parke, Guneet S Sodhi, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Ophthalmology|August 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR TrialJean-François Korobelnik, Paolo Lanzetta, Sergio Leal, et al.
Expert Opinion on Biological Therapy|February 2, 2023
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey)Ashish Sharma, Frank G Holz, Carl D Regillo, et al.
Pageof 3